AnaptysBio, Inc. (ANAB)

NASDAQ: ANAB · USD

$50.4

+0.76 (+1.5%)· Recorded snapshot

Market cap	1.5B
Revenue (ttm)	106.1M
Net income (ttm)	262M
EPS (ttm)	$7.00
Shares out	29.9M
P/E (trailing)	7.2x
P/E (forward)	17.9x
Volume	249,431
Beta	0.45

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 106.1M
Net income (ttm): 262M
EPS (ttm): $7.00
P/E (trailing): 7.2x
P/E (forward): 17.9x
Market cap: 1.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E17.9

P25 n/aP50 n/aP75 n/a

Trailing P/E7.2

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC109.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ANAB indicators

Market & fundamental data

Available fields

217

Groups with data

Currency

USD

Showing 217 of 217 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001370053
Company name	AnaptysBio, Inc.
Country	United States
Country code	US
CUSIP number	032724106
Earnings date	2026-11-10
Earnings time	amc
Employees	104
Employees change	-32
Employees growth	-23.53%
Enterprise value	$1.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	June
Founded	2005
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2017-01-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US0327241065
Last 10-K release date	2026-03-03
Last earnings date	2026-09-21
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.5B
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$50.39
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ANAB
U.S. state	California
Website	https://www.anaptysbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	13.89%
EV/Earnings	6.07x
EV/EBIT	24.22x
EV/EBITDA	24.21x
EV/Sales	15x
FCF / EV yield	-6.61%
FCF yield	-7.08%
Forward EV/Sales	12.18x
Forward P/E	17.94x
Forward P/S	11.38x
Graham number	7.48819
Graham upside	-84.93%
P/B ratio	139.39x
P/E ratio	7.2x
P/S ratio	14x
Price / tangible book value	140.34x
Price/EBITDA ratio	22.61x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	61.93%
EBITDA margin	61.94%
Gross margin	105.03%
Operating margin	61.93%
Pretax margin	-9.6%
Profit margin	246.96%
Profit per employee	$2.5M
Profitable quarters	1
Revenue per employee	$1M
ROCE	23.33%
ROIC	109.79%
ROIC (5Y)	1.89%
SBC / revenue	15.69%
Tax / revenue	-342.08%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
Gross profit growth (Q)	27.33%
Gross profit growth 5Y	59.88%
Net income growth quarters	1
Net income growth years	2
Operating income growth (Q)	-25.61%
Revenue growth	-13.86%
Revenue growth (QoQ)	7.56%
Revenue growth 10Y	18.57%
Revenue growth 3Y	101.67%
Revenue growth 5Y	0.93%
Revenue growth quarters	1
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-69,000
Depreciation and amortization	$18,000
EBIT	$65.7M
EBITDA	$65.7M
EPS	$7.00
FCF per share	$-3.52
Financing cash flow	$-188.7M
Free cash flow	$-105.1M
Free cash flow minus SBC	$-121.8M
Gross profit	$111.4M
Income taxes	$-362.9M
Investing cash flow	$85.1M
Net cash flow	$-208.7M
Net income	$262M
Operating cash flow minus SBC	$-121.8M
Operating income	$65.7M
Revenue	$106.1M
Stock-based compensation	$16.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.24
Book value per share	$0.36
Debt / EBITDA	4.1
Debt / equity	25.47
Interest coverage	0.8
Long-term assets	$118.6M
Long-term liabilities	$271M
Net cash (debt)	$-105.4M
Net cash / market cap	-7.1%
Net debt / EBITDA	1.6
Net debt / equity	9.96
Piotroski F-Score	3
Property, plant and equipment	$11.7M
Shareholders' equity	$10.6M
Tangible book value	$10.6M
Tangible book value per share	$0.36
Total assets	$317M
Total cash	$164.1M
Total debt	$269.6M
Total liabilities	$306.4M
WACC	9.41%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$198.4M
Current liabilities	$35.4M
Current ratio	5.61
Net working capital	$1.1M
Quick ratio	5.54
Working capital	$163.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-26.17%
Dividend yield	0%
Shareholder yield	-26.17%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$57.10
1D price change	1.53%
1M price change	-2.37%
1M total return	-2.37%
1W price change	9.6%
1W total return	9.6%
1Y price change	37.62%
1Y return CAGR	106.56%
1Y total return	106.46%
20-day SMA	$47.67
200-day SMA	$56.50
3M price change	-7.13%
3M total return	-7.13%
3Y price change	204.53%
3Y return CAGR	65.91%
3Y total return	356.86%
50-day SMA	$52.12
50-day SMA vs 200-day SMA	50under200
52-week high	$73.30
52-week high date	2026-04-13
52-week low	$30.27
52-week low date	2025-11-10
5Y price change	60.1%
5Y return CAGR	19.16%
5Y total return	140.18%
6M price change	-25.23%
6M total return	-25.23%
After-hours change	2.98%
After-hours close	$50.39
After-hours price	$51.89
All-time high	$134.00
All-time high date	2018-02-20
All-time low	$10.00
All-time low date	2019-11-08
Average true range (ATR)	$2.30
Average volume	501.8K
Beta (1Y)	0.55
Beta (2Y)	0.78
Beta (5Y)	0.45
Change from 52-week high	-31.26%
Change from 52-week low	66.47%
Change from all-time high	-62.84%
Change from all-time low	397.9%
Change from open	1.61%
Day's gap	-0.08%
Dollar volume	$12.6M
High price	$50.39
Low price	$49.24
Monthly RSI	55.42
Open price	$49.59
Position in 52-week range	100%
Premarket change	-0.24%
Premarket close	$49.63
Premarket price	$49.51
Premarket volume	1.6K
Previous close	$49.63
Price vs 150-day SMA	-12.81%
Price vs 20-day SMA	4.46%
Price vs 200-day SMA	-11.87%
Price vs 50-day SMA	-4.48%
Relative volume	0.5
RSI	51.75
Sharpe ratio	1.41
Sharpe ratio (3Y)	0.98
Sharpe ratio (5Y)	0.56
Sortino ratio	2.28
Sortino ratio (3Y)	1.58
Sortino ratio (5Y)	0.94
Volume	249.4K
Weekly RSI	45.52
YTD price change	2.7%
YTD total return	54.08%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	20.5M
Float percentage	68.56%
Shares change (QoQ)	25.39%
Shares change (YoY)	26.17%
Shares held by insiders	2.33%
Shares held by institutions	79.39%
Shares outstanding	29.9M
Short % of float	26.31%
Short % of shares	18.04%
Short ratio	9 days

Deeper analysis on ANAB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ANAB report

Is a complete ANAB research report available?

No complete published report is available for AnaptysBio, Inc. (ANAB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

AnaptysBio, Inc. (ANAB)

Price

Financial snapshot

Fair-value bridge

Latest news · ANAB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ANAB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ANAB

Frequently asked questions